Halozyme Therapeutics (HALO) Cash from Investing Activities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Investing Activities data on file, last reported at -$2.9 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 96.82% year-over-year to -$2.9 million in Q1 2026; TTM through Mar 2026 was -$458.3 million, a 69.44% decrease from a year earlier, with the FY2025 full-year figure at -$545.8 million, down 107.75% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$2.9 million, up from -$741.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for HALO reached as high as $201.6 million in Q3 2025 and fell as low as -$741.8 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$82.1 million across 5 years, with a median of -$42.0 million in 2024.
• Across the five-year window, Cash from Investing Activities sank 8178.77% in 2023 and soared 455.57% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$1.7 million in 2022, then sank by 374.86% to -$8.3 million in 2023, then surged by 455.57% to $29.5 million in 2024, then sank by 2616.24% to -$741.8 million in 2025, then soared by 99.61% to -$2.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.9 million in Q1 2026, -$741.8 million in Q4 2025, and $201.6 million in Q3 2025.